LABU - Direxion Daily S&P Biotech Bull 3X ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
45.88
+1.69 (+3.82%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close44.19
Open43.88
Bid43.00 x 800
Ask47.00 x 1000
Day's Range41.55 - 46.38
52 Week Range38.90 - 116.54
Volume4,006,722
Avg. Volume2,909,807
Net Assets677.55M
NAV51.09
PE Ratio (TTM)N/A
Yield0.22%
YTD Return-34.37%
Beta (3Y Monthly)6.26
Expense Ratio (net)1.02%
Inception Date2015-05-28
Trade prices are not sourced from all markets
  • ETF Trendslast month

    Biotech ETFs Hoping This Post-Election Trend Doesn’t Repeat

    Stocks rallied Wednesday, a day after one of the most contentious midterm elections in U.S. history. In Tuesday's midterm elections, Democrats emerged with control of the House while Republicans maintained control of the Senate. Among the winning exchange traded funds Wednesday were biotechnology funds, including the SPDR S&P Biotech ETF (XBI) , which takes an equal-weight approach to the biotech space.

  • ETF Trendslast month

    After a Rough October, Leveraged Biotech ETF Looks to Bounce Back

    Biotechnology stocks and exchange traded funds participated in the October broader market swoon, punishing funds such as the Direxion Daily S&P Biotech Bull Shares (LABU) in the process. LABU, which takes the 3x or 300% daily performance of the S&P Biotechnology Select Industry Index, is attempting to reverse its October slide this month and is off to a good start with a November gain of about 14%. The slump in once hot biotechnology ETFs could present investors with a buying opportunity.

  • 5 Leveraged ETFs for Active Traders
    InvestorPlace2 months ago

    5 Leveraged ETFs for Active Traders

    Few asset classes are as seductive as leveraged exchange-traded funds (ETFs). Other than leveraged ETFs, where else in the fund universe (without using options) can investors make a bet on a simple index, such as the S&P 500 or Nasdaq-100 Index, and amplify those benchmarks’ gains to the tune of 200% or even 300% in a single trading day?

  • How the Biotech Sector Has Fared this Year
    Market Realist3 months ago

    How the Biotech Sector Has Fared this Year

    Usually, when investors add biotechnology stocks to their portfolios, they feel confident about risk. When they want to reduce risk, biotech names are the first to go. LABU (3X Biotech Bull) and LABD (3X Biotech Bear) can help you stay risk-on or risk-off.

  • Benzinga5 months ago

    Exploring The Leveraged ETF Trade Heading Into Earnings Season

    Many institutional traders use multi-faceted strategies that involve several different instruments when trading around an earnings report. Among the most common hedging tools used by institutions are leveraged ETFs, which are built to deliver multiples (or inverse multiples) on a given index. “They aren’t meant to be held for more than a few days at a time,” Sylvia Jablonski, managing director of leveraged ETF provider Direxion ETFs said.

  • ETF Trends5 months ago

    Pharma, Biotech Bull ETFs Leading the Charge

    The rising prices of drug treatments, more dependence on immuno-oncology and mergers focused on mid-sized biotech company acquisitions are just a few factors spurning the growth in the biotechnology and pharmaceuticals industry, giving ETFs like  Daily Pharmaceutical & Medical Bull 3X Shares  (PILL) and Direxion Daily S&P Biotech Bull 3X ETF (LABU) exceptional returns. PILL seeks investment results equal to 300% of the daily performance of the Dynamic Pharmaceutical Intellidex Index and concentrates its allocations towards securities of the index and other financial instruments that provide daily leveraged exposure to the index. The index itself just matched a previous high and PILL itself is posting year-to-date returns of 6.36% according to performance figures from Yahoo! Finance.

  • ETF Trends6 months ago

    5 Big Direxion ETFs Trending This Week

    Since 1997, Direxion has been providing investment solutions with their innovative ETFs and 20 years later, they have $13.4 billion worth of assets under management. If you haven't already, check out the 5 ETFs below that are trending this week - and are worth keeping an eye on during the second half of 2018. Despite all the talk regarding trade wars with the United States and China, one sector that has been shrugging off the market noise is the biotechnology sector.

  • Biotech Sector Continue to Dazzle Despite Market Distress
    Market Realist6 months ago

    Biotech Sector Continue to Dazzle Despite Market Distress

    Biotech stocks—with their binary outcomes and potential FDA approvals or denials—should whip around, pending various outcomes. It doesn’t help that President Trump (seemingly at random) decides periodically that we all pay too much for drugs. For biotech stocks to work on the long side investors’ risk appetite would have to take off or a major approval could drive the stocks up.

  • ETF Trends8 months ago

    Catalysts Abound for Biotech ETFs

    Biotechnology stocks and biotech ETFs tumbled in the back half of March and to start April. For example, the SPDR S&P Biotech ETF (NYSEArca: XBI) came into Monday with a loss of almost 12.6% over the past ...

  • Investopedia10 months ago

    Biotech Stocks Trade Near Major Levels of Support

    With biotech stocks tumbling toward long-term levels of support, we take a closer look at how active traders will trade the bounce.

  • ETF Trends10 months ago

    Healthcare Dip Could be a Buying Opportunity

    The Health Care Select Sector SPDR (NYSEArca: XLV), the largest exchange traded fund dedicated to the S&P 500’s third-largest sector weight, tumbled last week, but some market observers believe the decline ...

  • 5 Best-Performing Leveraged ETFs of January
    Zacks10 months ago

    5 Best-Performing Leveraged ETFs of January

    Demand for leveraged ETFs is growing as investors seek to register big gains in a short span.

  • The Zacks Analyst Blog Highlights: NAIL, CWEB, LABU, SOXL and EDC
    Zacks11 months ago

    The Zacks Analyst Blog Highlights: NAIL, CWEB, LABU, SOXL and EDC

    The Zacks Analyst Blog Highlights: NAIL, CWEB, LABU, SOXL and EDC